FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Export data to Excel for your own analysis. here On average, they expect X4 Pharmaceuticals' share price to reach $18.20 in the next year. Get short term trading ideas from the MarketBeat Idea Engine. The inducement awards consist of options to purchase an aggregate of 30,500 shares of X4’s common stock and were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4). All rights reserved. Their forecasts range from $15.00 to $21.00. Its products in pipeline include X4P-001, X4P-002, and X4P-003. X4 Pharmaceuticals has received no research coverage in the past 90 days. View analysts' price targets for X4 Pharmaceuticals. Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($2.79) to ($2.50) per share. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Only 3.80% of the stock of X4 Pharmaceuticals is held by insiders. Get daily stock ideas top-performing Wall Street analysts. Should Investors Grab a Slice of Domino's Pizza Stock? Vote “Outperform” if you believe XFOR will outperform the S&P 500 over the long term. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Intraday data delayed at least 15 minutes or per exchange requirements. According to analysts' consensus price target of $18.20, X4 Pharmaceuticals has a forecasted upside of 159.6% from its current price of $7.01. Please log in to your account or sign up in order to add this asset to your watchlist. Advanced Stock Screeners and Research Tools Terms of Use Privacy Policy Disclosures Member User Agreement Corrections Cookies. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Commerce Policy | X4 Pharmaceuticals has received a consensus rating of Buy. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Off the beaten road: The 2021 Jeep Gladiator reviewed, Too good to be true? Intraday Data provided by FACTSET and subject to terms of use. Get short term trading ideas from the MarketBeat Idea Engine. Does your estate plan use the right type of Power of Attorney for you? X4 Pharmaceuticals does not currently pay a dividend. The stock was sold at an average price of $7.00, for a total value of $12,579.00. Updated daily, it takes into Since then, XFOR shares have decreased by 18.3% and is now trading at $7.01. View Arsanis Inc XFOR investment & stock information. Stock analysis for X4 Pharmaceuticals Inc (XFOR:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. balance sheet and inputs from the stock market. Learn everything you need to know about successful options trading with this three-part video course. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.06. Get the latest X4 Pharmaceuticals, Inc. (XFOR) stock news and headlines to help you in your trading and investing decisions. fair value, and uncertainty rating. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. © 2020 Insider Inc. and finanzen.net GmbH (Imprint). For more information, please visit www.x4pharma.com.Investors and Media: Candice Ellis, 857-341-1043 Director, Corporate Communications & Investor Relations Candice.ellis@x4pharma.com, X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the expansion of its board of directors with the appointment of Alison Lawton, a biopharmaceutical industry veteran with more than 30 years of experience in a wide range of senior executive and operational roles. Stock quote and company snapshot for X4 PHARMACEUTICALS INC (XFOR), including profile, stock chart, recent news and events, analyst opinions, and research reports. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Stock quotes by finanzen.net. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s The Company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. click X4 Pharmaceuticals has received 52 “outperform” votes. Based on an average daily volume of 101,200 shares, the days-to-cover ratio is presently 2.9 days. © 2020 Verizon Media. . View our earnings forecast for X4 Pharmaceuticals. xfor The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom’s macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). How to buy a salvage-title vehicle, Podcast: $10 Billion in Sales Expected From Amazon’s Delayed Prime Day. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. See what's happening in the market right now with MarketBeat's real-time news feed. X4 Pharmaceuticals does not have a long track record of dividend growth. View which stocks are hot on social media with MarketBeat's trending stocks report. Disclaimer | To see all exchange delays and terms of use please see disclaimer. employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics * Average Estimates in Million (e.g. Currency in USD, Trade prices are not sourced from all markets. View our full suite of financial calendars and market data tables, all for free. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Do Not Sell My Information. Subscriber Agreement & Terms of Use, Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Receive a free world-class investing education from MarketBeat. Historical and current end-of-day data provided by FACTSET. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate.